These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34779394)

  • 1. Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy.
    Cancanelli L; Mengato D; Di Spazio L; Rivano M; Chiumente M; Messori A
    Int J Clin Pharmacol Ther; 2022 Jan; 60(1):32-35. PubMed ID: 34779394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
    Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
    Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS
    Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.
    Mengato D; Cancanelli L; Di Spazio L; Rivano M; Chiumente M; Messori A
    Int J Clin Pharmacol Ther; 2022 Aug; 60(8):370-372. PubMed ID: 35652551
    [No Abstract]   [Full Text] [Related]  

  • 5. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis.
    Lin Q; Liu W; Xu S; Shang H; Li J; Guo Y; Tong J
    BJOG; 2021 Feb; 128(3):485-493. PubMed ID: 32654312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
    Park J; Lim MC; Lee JK; Jeong DH; Kim SI; Choi MC; Kim BG; Lee JY
    J Gynecol Oncol; 2022 Mar; 33(2):e12. PubMed ID: 34910393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
    Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
    Gong H; Nie D; Huang Y; Li Z
    Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
    Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
    Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
    Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP Inhibitors in Ovarian Cancer.
    Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
    Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    Kurnit KC; Coleman RL; Westin SN
    Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
    Kaneko M
    Ann Pharmacother; 2022 Jan; 56(1):27-34. PubMed ID: 33926263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
    Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C
    Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitors in ovarian cancer.
    Franzese E; Centonze S; Diana A; Carlino F; Guerrera LP; Di Napoli M; De Vita F; Pignata S; Ciardiello F; Orditura M
    Cancer Treat Rev; 2019 Feb; 73():1-9. PubMed ID: 30543930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis.
    Feng Y; Huang H; Wan T; Zhang C; Tong C; Liu J
    Adv Ther; 2019 Dec; 36(12):3368-3380. PubMed ID: 31599396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
    Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
    Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ;
    N Engl J Med; 2019 Dec; 381(25):2391-2402. PubMed ID: 31562799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.